Retension Pharmaceuticals Inc. (NASDAQ: RTSN) Stock Competitors & Peer Comparison
See RTSN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RTSN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RTSN | $11.30 | -0.53% | 43.6M | -4.45 | -$2.61 | N/A |
| RPRX | $66.52 | -0.98% | 29.6B | 12.67 | $5.25 | +1.38% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| CORT | $80.46 | -0.81% | 8.7B | 229.89 | $0.35 | N/A |
| KNSA | $90.80 | -1.56% | 7.1B | 69.77 | $1.30 | N/A |
| LQDA | $41.85 | -7.12% | 3.7B | 30.55 | $1.37 | N/A |
| PBH | $49.73 | +1.37% | 2.4B | 11.26 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $13.51 | -3.15% | 811.5M | -5.35 | -$2.52 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
RTSN vs RPRX Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, RPRX has a market cap of 29.6B. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while RPRX trades at $66.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas RPRX's P/E ratio is 12.67. In terms of profitability, RTSN's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, RTSN is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check RPRX's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
RTSN vs WBA Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas WBA's P/E ratio is -1.64. In terms of profitability, RTSN's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, RTSN is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check WBA's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
RTSN vs CORT Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, CORT has a market cap of 8.7B. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while CORT trades at $80.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas CORT's P/E ratio is 229.89. In terms of profitability, RTSN's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, RTSN is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check CORT's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
RTSN vs KNSA Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, KNSA has a market cap of 7.1B. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while KNSA trades at $90.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas KNSA's P/E ratio is 69.77. In terms of profitability, RTSN's ROE is N/A, compared to KNSA's ROE of +0.17%. Regarding short-term risk, RTSN is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
RTSN vs LQDA Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while LQDA trades at $41.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas LQDA's P/E ratio is 30.55. In terms of profitability, RTSN's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, RTSN is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
RTSN vs PBH Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while PBH trades at $49.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas PBH's P/E ratio is 11.26. In terms of profitability, RTSN's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, RTSN is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
RTSN vs HROWL Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas HROWL's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, RTSN is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
RTSN vs HROWM Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas HROWM's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, RTSN is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
RTSN vs LTGO Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, LTGO has a market cap of 811.5M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while LTGO trades at $13.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas LTGO's P/E ratio is -5.35. In terms of profitability, RTSN's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, RTSN is more volatile compared to LTGO. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
RTSN vs HELP Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, HELP has a market cap of 545.5M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while HELP trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas HELP's P/E ratio is -2.11. In terms of profitability, RTSN's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, RTSN is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
RTSN vs SVA Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas SVA's P/E ratio is -5.68. In terms of profitability, RTSN's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, RTSN is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
RTSN vs CUVL Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, CUVL has a market cap of 249.9M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while CUVL trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas CUVL's P/E ratio is 10.68. In terms of profitability, RTSN's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, RTSN is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
RTSN vs HITI Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, HITI has a market cap of 230.9M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while HITI trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas HITI's P/E ratio is -9.57. In terms of profitability, RTSN's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, RTSN is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
RTSN vs CELG-RI Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, CELG-RI has a market cap of 194.1M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, RTSN is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check CELG-RI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
RTSN vs ETRA Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, ETRA has a market cap of 155.1M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while ETRA trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas ETRA's P/E ratio is -2.76. In terms of profitability, RTSN's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, RTSN is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
RTSN vs TRXB Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, TRXB has a market cap of 114.4M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while TRXB trades at $13.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas TRXB's P/E ratio is -5.56. In terms of profitability, RTSN's ROE is N/A, compared to TRXB's ROE of N/A. Regarding short-term risk, RTSN is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check TRXB's competition here
Atlantic International Corp. (NASDAQ: ATLN)
RTSN vs ATLN Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas ATLN's P/E ratio is -0.68. In terms of profitability, RTSN's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, RTSN is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
RTSN vs CTOR Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, CTOR has a market cap of 55.2M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while CTOR trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas CTOR's P/E ratio is -1.26. In terms of profitability, RTSN's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, RTSN is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check CTOR's competition here
Rite Aid Corporation (NYSE: RAD)
RTSN vs RAD Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas RAD's P/E ratio is -0.05. In terms of profitability, RTSN's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, RTSN is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
RTSN vs GLTO Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas GLTO's P/E ratio is -1.78. In terms of profitability, RTSN's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, RTSN is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check GLTO's competition here
Cosmos Health Inc. (NASDAQ: COSM)
RTSN vs COSM Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, COSM has a market cap of 31.1M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while COSM trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas COSM's P/E ratio is -0.42. In terms of profitability, RTSN's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, RTSN is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check COSM's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
RTSN vs NSRX Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, NSRX has a market cap of 27.6M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while NSRX trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas NSRX's P/E ratio is -4.44. In terms of profitability, RTSN's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, RTSN is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
RTSN vs SCYX Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, SCYX has a market cap of 24M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while SCYX trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas SCYX's P/E ratio is -1.11. In terms of profitability, RTSN's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, RTSN is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check SCYX's competition here
Pomdoctor Limited (NASDAQ: POM)
RTSN vs POM Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, POM has a market cap of 16.4M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while POM trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas POM's P/E ratio is -0.28. In terms of profitability, RTSN's ROE is N/A, compared to POM's ROE of +0.80%. Regarding short-term risk, RTSN is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check POM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
RTSN vs BFRI Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, BFRI has a market cap of 13M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while BFRI trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas BFRI's P/E ratio is -1.59. In terms of profitability, RTSN's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, RTSN is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
RTSN vs CNSY Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, CNSY has a market cap of 12.9M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while CNSY trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas CNSY's P/E ratio is -0.41. In terms of profitability, RTSN's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, RTSN is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check CNSY's competition here
Azora Therapeutics, Inc. (NASDAQ: AZR)
RTSN vs AZR Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, AZR has a market cap of 10.4M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while AZR trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas AZR's P/E ratio is -0.24. In terms of profitability, RTSN's ROE is N/A, compared to AZR's ROE of N/A. Regarding short-term risk, RTSN is less volatile compared to AZR. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check AZR's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
RTSN vs CJJD Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas CJJD's P/E ratio is -0.46. In terms of profitability, RTSN's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, RTSN is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
RTSN vs SSY Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas SSY's P/E ratio is -2.86. In terms of profitability, RTSN's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, RTSN is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
RTSN vs SCNX Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while SCNX trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas SCNX's P/E ratio is -1.54. In terms of profitability, RTSN's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, RTSN is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check SCNX's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
RTSN vs BGMS Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, BGMS has a market cap of 5M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while BGMS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas BGMS's P/E ratio is -0.25. In terms of profitability, RTSN's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, RTSN is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check BGMS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
RTSN vs MDVL Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas MDVL's P/E ratio is -0.05. In terms of profitability, RTSN's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, RTSN is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check MDVL's competition here
Eocene Ltd. (NASDAQ: EOCN)
RTSN vs EOCN Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, EOCN has a market cap of 2.8M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while EOCN trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas EOCN's P/E ratio is -0.19. In terms of profitability, RTSN's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, RTSN is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
RTSN vs PAVS Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, PAVS has a market cap of 2.7M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while PAVS trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas PAVS's P/E ratio is -0.03. In terms of profitability, RTSN's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, RTSN is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check PAVS's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
RTSN vs ATNFW Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas ATNFW's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, RTSN is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
RTSN vs BGMSP Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, RTSN's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, RTSN is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
RTSN vs AZNH Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas AZNH's P/E ratio is 38.35. In terms of profitability, RTSN's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, RTSN is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check AZNH's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP)
RTSN vs ASBP Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, ASBP has a market cap of 842.2K. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while ASBP trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas ASBP's P/E ratio is -0.31. In terms of profitability, RTSN's ROE is N/A, compared to ASBP's ROE of +19.93%. Regarding short-term risk, RTSN is more volatile compared to ASBP. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check ASBP's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
RTSN vs BFRIW Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while BFRIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas BFRIW's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, RTSN is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check BFRIW's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
RTSN vs LFLYW Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, RTSN's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, RTSN is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check LFLYW's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW)
RTSN vs ASBPW Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, ASBPW has a market cap of 149.5K. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while ASBPW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas ASBPW's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, RTSN is less volatile compared to ASBPW. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check ASBPW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
RTSN vs PRPH Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, PRPH has a market cap of 91.1K. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas PRPH's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, RTSN is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check PRPH's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
RTSN vs OREX Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, OREX has a market cap of 0. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas OREX's P/E ratio is -0.14. In terms of profitability, RTSN's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, RTSN is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for RTSN.Check OREX's competition here
Shire plc (NASDAQ: SHPG)
RTSN vs SHPG Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas SHPG's P/E ratio is 11.35. In terms of profitability, RTSN's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, RTSN is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check SHPG's competition here
POZEN Inc. (NASDAQ: POZN)
RTSN vs POZN Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, POZN has a market cap of 0. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas POZN's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, RTSN is more volatile compared to POZN. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check POZN's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
RTSN vs ESRX Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas ESRX's P/E ratio is 10.69. In terms of profitability, RTSN's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, RTSN is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
RTSN vs IPXL Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas IPXL's P/E ratio is -10.11. In terms of profitability, RTSN's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, RTSN is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check IPXL's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
RTSN vs CPD Comparison November 2026
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RTSN stands at 43.6M. In comparison, CPD has a market cap of 0. Regarding current trading prices, RTSN is priced at $11.30 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RTSN currently has a P/E ratio of -4.45, whereas CPD's P/E ratio is N/A. In terms of profitability, RTSN's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, RTSN is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for RTSN.Check CPD's competition here